Important Part
Based on these high-impact publications the view was that LSD effects cannot be antagonized and it was therefore not obvious that this can be done with ketanserin. Based on pharmacokinetic-pharmacodynamic modeling data and the present human study the present patent application showed an unexpected effect of ketanserin to reverse the LSD response. The fact that ketanserin has been used in preclinical experiments and in humans to prevent the response to LSD is not an obvious indication of antagonism when used after LSD in the light of the scientific published data. There was no preclinical or clinical data using ketanserin to reverse LSD responses in vivo prior to the present patent application.
Therefore, the combination of Kraehenmann, et al. and Peters, et al. does not disclose or suggest the present invention, and the unexpected results overcome the prima facie obvious rejection.
Since neither the cited references alone or in combination with knowledge in the art suggest the currently claimed invention, it is consequently respectfully submitted that the claims are clearly patentable over the combination, even if the combination were to be applied in opposition to applicable law, and reconsideration of the rejection is respectfully requested.
The remaining dependent claims not specifically discussed herein are ultimately dependent upon the independent claims. References as applied against these dependent claims do not make up for the deficiencies of those references as discussed above, and the prior art references do not disclose the characterizing features of the independent claims discussed above. Hence, it is respectfully submitted that all of the pending claims are patentable over the prior art.
In conclusion, it is respectfully requested that the present amendment be entered in order to place the application in condition for allowance, which allowance is respectfully requested.
News 
Market Data 
Discover 
